- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06417281
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)
May 16, 2024 updated by: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
A Phase III Clinical Trial of Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid
This trial is an open-label, multicenter, phase III clinical study,conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder for fluorescence-guided tumor resection and photodynamic diagnosis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: jingsong wu, doctor
- Phone Number: +8613701707118
- Email: wujinsong@huashan.org.cn
Study Locations
-
-
-
Shanghai, China
- Huashan Hospital, Fudan University
-
Contact:
- jingsong wu, Doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient's written informed consent
- Age 18-75 years
- Radiological suspicion of a malignant glioma
- Indication for surgical tumour resection
- Karnofsky Performance Status (KPS) ≥ 70
Exclusion Criteria:
- Tumor located in the basal ganglia, thalamus, cerebellum, or brainstem
- Porphyria, hypersensitivity to porphyrins,history of cutaneous photosensitivity or photosensitive skin diseases;
- known hypersensitivity to the test drug ingredients
- Any other condition that, in the opinion of the investigator, makes participation in the trial inappropriate;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 5 Aminolevulinic Acid
This is an single arm study.
|
3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
positive predictive rate of tissue fluorescence per biopsy sample taken from fluorescent sites
Time Frame: within 48h after surgery
|
The proportion of biopsy tissues diagnosed as malignant glioma cells positive by pathological examination among all tissues collected from both fluorescent and weakly fluorescent areas.
|
within 48h after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
May 12, 2024
First Submitted That Met QC Criteria
May 12, 2024
First Posted (Actual)
May 16, 2024
Study Record Updates
Last Update Posted (Actual)
May 17, 2024
Last Update Submitted That Met QC Criteria
May 16, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F0009-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma of Brain
-
Annick DesjardinsAmgenTerminated
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
University of Alabama at BirminghamNot yet recruitingRecurrent Malignant Glioma | Glioblastoma Multiforme of Brain | Anaplastic Astrocytoma of Brain | Gliosarcoma of BrainUnited States
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Xuanwu Hospital, BeijingBeijing Mario Biotech Company; Hebei Senlang BIotech Company; Beijing HuiNengAn...RecruitingGlioma | Malignant Glioma of Brain | Recurrence TumorChina
-
Dana-Farber Cancer InstituteNational Institutes of Health (NIH); Candel Therapeutics, Inc.RecruitingGlioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | Ependymoma | Ganglioglioma | Oligodendroglioma | Malignant Astrocytoma | Anaplastic Oligodendroglioma of Brain (Diagnosis) | Mixed Oligo-Astrocytoma | Pylocytic/Pylomyxoid AstrocytomaUnited States
-
Northwell HealthOlympus CorporationRecruitingMalignant Glioma of BrainUnited States
-
Novelwise Pharmaceutical CorporationRecruitingMalignant Neoplasm | Malignant Neoplasm of BrainTaiwan
Clinical Trials on 5 Aminolevulinic Acid
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
NorthShore University HealthSystemWithdrawn
-
medac GmbHCompletedBrain Cancer | Brain Tumors | Brain Tumor, Primary | Primary Brain Tumors | Cancer of Brain
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
St. Olavs HospitalOslo University Hospital; Norwegian University of Science and TechnologyCompletedCutaneous T-Cell Lymphoma, Unspecified | Chronic Graft Versus Host Disease in SkinNorway
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting
-
medac GmbHIKPCompleted
-
Southern Illinois UniversityDUSA Pharmaceuticals, Inc.CompletedBrain NeoplasmsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedGlioma | AstrocytomaUnited States
-
Andrew Sloan, MDCompletedBrain and Central Nervous System TumorsUnited States